NEW YORK, Nov. 14, 2012 /PRNewswire/ --IntelliCell    BioSciences, Inc. ("Company") (SVFC) announced today it will present at    the Marcus Evans 10th Annual Commercialization of    Regenerative Medicine in London, UK on the 28-30th    November 2012. The Company will also be conducting a    half-day pre-conference workshop addressing market entry    strategies for emerging regenerative medicine companies.  
    IntelliCell's EVP Clinical Development, Robert Sexauer, stated    "Our Company is very pleased to be participating in this well    established conference for emerging regenerative medicine    technologies. Over the past several years, our management    team has processed over 10,000 autologous cellular products and    we are happy to share our insights regarding market entry    strategies for emerging companies in our industry. We    want to see the entire regenerative medicine industry continue    to develop compliant processes, systems, and practices for    better medicine"  
    Dr. Steven Victor, Chairman and CEO of IntelliCell stated "This    is an exciting time for regenerative medicine companies.    IntelliCell is taking a thought leadership role in the    translation of technologies from the research laboratories and    into clinical practice. Our objective is to continue to    harmonize the requirements of regulators, clinicians, and    patients receiving these profound new treatments."  
    About IntelliCell BioSciences  
    IntelliCell BioSciences is a Regenerative Medicine company    developing novel technologies that address the regenerative,    curative, and preventative conditions of disease states with    high unmet clinical needs. The Company has several patent    pending applications including an industry unique method of    obtaining autologous stromal vascular fraction cells (SVF) from    the vasculature surrounding adipose tissue containing adult    stem cells and a robust population of regenerative healing    cells. The Company is also pioneering the development of    autologous and allogeneic cells from living and non-living    tissue donors for research purposes. IntelliCell is    planning a series of in-human clinical studies with top tier    universities for the treatment of osteoarthritis, multiple    sclerosis, lower limb ischemic wounds, and gum regeneration in    the oral cavity as well as medical aesthetics. The    Company has developed a first in class cGTP cellular processing    facility in New York City, purpose built and designed to be    fully integrated into its ambulatory surgery center.  
    Forward-LookingStatementsCertain    statements set forth in this press release constitute    "forward-looking statements." Forward-looking statements    include, without limitation, any statement that may predict,    forecast, indicate, or imply future results, performance or    achievements, and may contain the words "estimate," "project,"    "intend," "forecast," "anticipate," "plan," "planning,"    "expect," "believe," "will likely," "will reach," "will    change," "will soon," "should," "could," "would," "may," "can"    or words or expressions of similar meaning. Such statements are    not guarantees of future performance and are subject to risks    and uncertainties that could cause the company's actual results    and financial position to differ materially from those included    within the forward-looking statements. Forward-looking    statements involve risks and uncertainties, including those    relating to the Company's ability to grow its business. Actual    results may differ materially from the results predicted and    reported results should not be considered as an indication of    future performance. The potential risks and uncertainties    include, among others, the Company's limited operating history,    the limited financial resources, domestic or global economic    conditions, activities of competitors and the presence of new    or additional competition, and changes in Federal or State    laws. More information about the potential factors that could    affect the Company's business and financial results is included    in the Company's filings, available via the United States    Securities and Exchange Commission.  
    Contacts:  
    IntelliCell BioSciences, Inc.    Angela Metelitsa    Email Contact:     ametelitsa@intellicellbiosciences.com    (646) 576-8708   
See original here:
IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of ...